Combining hiPSC-CMs and in-silico modeling reveals that mavacamten is effective for thick filament HCM mutations but less so for thin filament mutations, highlighting the need for targeted pharmacogenetics.
Abstract Cardiomyopathies have unresolved genotype-phenotype relationships and lack disease-specific treatments. Here we identify genotype-specific pathomechanisms and therapeutic targets combining experimental hiPSC-CM modelling and human-based cardiac electromechanical in-silico modelling and simulation bridging from specific mutations to clinical biomarkers. We select hypertrophic cardiomyopathy as a challenge for this approach and study genetic variations that mutate proteins of the thick ( MYH7 R403Q/+ ) and thin filaments ( TNNT2 R92Q/+ , TNNI3 R21C/+ ) of the cardiac sarcomere. We show that destabilisation of myosin super relaxation drives disease in MYH7 R403Q/+ with secondary effects on thin filament activation, which are corrected by Mavacamten. Thin filament variants TNNT2 R92Q/+ and TNNI3 R21C/+ share calcium regulation-related pathomechanisms, for which Mavacamten provides incomplete salvage. We define the ideal characteristics of a novel thin filament-targeting compound and show its efficacy in-silico. We demonstrate that hybrid human-based hiPSC-CM and in-silico studies accelerate pathomechanism discovery and classification testing, improving clinical interpretation of genetic variants, and directing rational therapeutic targeting and design.
Margara et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: